Fumaining (Luvometinib) – NF1-PN | HongKong DengYue Medicine

Luvometinib Application Scope

• Treatment of Langerhans Cell Histiocytosis (LCH)

• Histiocytic Tumors

• Neurofibromatosis Type 1 (NF1) with inoperable Plexiform Neurofibroma (PN) in pediatric patients (≥2 years old) and adolescents

  

Luvometinib Characteristics

• Ingredients: Luvometinib

• Properties:​ Oral kinase inhibitor, selective MEK1/2 inhibitor

• Packaging Specification:​ Tablets, 4 mg

• Storage:​ Store at room temperature, keep in a dry place away from light.

• Expiry Date: 24 months

• Executive Standard: ​National Drug Standard of China

• Approval Number: H20250025 / H20250026

• Date of Revision: 2025-05

• Manufacturer: Fosun Pharma / Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.

Guidelines for the Use of Fumaining

• Dosage and Administration:

  • Recommended Dose: 20–40 mg once or twice daily (adjusted according to patient condition and tolerance)

  • Administration: Swallow whole with water, do not crush or chew

  • Missed Dose:​ If a dose is missed, take it as soon as possible; if close to the next dose, skip the missed dose, do not double up

• Adverse Reactions:

  • Common Adverse Reactions:

    • Rash

    • diarrhea

    • nausea

    • fatigue

    • edema

    • increased liver enzymes

  • Serious Adverse Reactions:

    • Severe skin reactions

    • interstitial lung disease

    • cardiotoxicity

    • ocular disorders

      ​

• Contraindications:

  • Known hypersensitivity to Luvometinib or excipients

• Precautions:

  • Monitor liver function, cardiac function, and ocular health during treatment.

  • Use with caution in patients with hepatic or renal impairment.

  • Avoid pregnancy and breastfeeding during and after treatment.

Luvometinib Interactions

• Avoid co-administration with strong CYP3A4 inhibitors or inducers.

• May interact with drugs affecting liver enzyme metabolism

• Monitor for additive toxicities with other anti-cancer agents.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.